JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

JAK inhibitors have promising therapeutic potential in COVID-19 with dual anti-inflammatory and anti-viral effects. Vigilance to the potentially increased thrombotic risk associated with JAKi is recommended, given the hypercoagulability of COVID-19. https://bit.ly/2NQ15K5

Detalles Bibliográficos
Autores principales: Mehta, Puja, Ciurtin, Coziana, Scully, Marie, Levi, Marcel, Chambers, Rachel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338400/
https://www.ncbi.nlm.nih.gov/pubmed/32631841
http://dx.doi.org/10.1183/13993003.01919-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338400/
https://www.ncbi.nlm.nih.gov/pubmed/32631841
http://dx.doi.org/10.1183/13993003.01919-2020

Ejemplares similares